Highest-materiality recent filing
IGC Pharma raises $514K via two convertible promissory notes with OID
FirstFire note: $346,910 principal at $307K purchase price, OID $39,910, 12% interest, matures April 10, 2027.
IGC Pharma partners with New to The Street for 12-part national media campaign
12-part campaign includes TV interviews on Fox Business and Bloomberg Television.
IGC Pharma issues $353K convertible note to Vanquish Funding; also obtains $219K loan
Principal $353,050 includes $46,050 original issue discount; net proceeds $307,000 for working capital.
IGC Pharma raises ~$234k in registered direct offering of 780k shares at $0.30/share
Issued 779,997 shares of common stock at $0.30 per share for gross proceeds of ~$234k.
IGC Pharma changes fiscal year-end from March 31 to December 31, effective 2025
Board approved fiscal year change from March 31 to December 31, effective Dec 31, 2025.
IGC Pharma increases authorized common stock from 150M to 600M shares
Amendment effective Dec 12, 2025, after stockholder approval on Oct 10, 2025.
IGC Pharma closes sale of Vancouver facility assets for ~$2.7M in non-cash consideration
Closed Nov 13, 2025; subsidiary Holi Hemp sold equipment, inventory, and leasehold assets to Wellness Essentials Northwest LLC.
IGC Pharma shareholders approve 4x increase in authorized shares to 600M and 5M share grant
Shareholders approved amendment to increase authorized common stock from 150M to 600M shares.
IGC Pharma subsidiary sells assets and facility to Wellness Essentials for ~$2.7M
Holi Hemp sold equipment, inventory, and Vancouver ready-to-move facility to Wellness Essentials Northwest.
IGC Pharma Phase 2 CALMA trial shows significant agitation reduction in Alzheimer's patients
Phase 2 interim: CMAI total score improvement -10.46 at week 6 (p=0.042, Cohen d=0.79) vs placebo.
IGC Pharma sells 588,235 shares to director-owned entity for $200,000 at $0.34 each
Shares issued to Moran Global Strategies, owned by director James Moran, at $0.34/share.
IGC Pharma stockholders re-elect two directors, ratify auditor, approve 5M share grant
Richard Prins (26,116,740 for) and Terry Lierman (27,800,503 for) re-elected as Class B directors until 2027.
IGC Pharma extends loan agreement with O-Bank; facility fees cut to $84,000 from $120,000
Extension effective July 8, 2024, extends term of existing Master Loan and Security Agreement under same terms.
IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation
Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.
IGC Pharma announces $3M private placement with Bradbury Asset Management at $0.34/share
Issued 8,823,529 unregistered common shares at $0.34/share to Bradbury Asset Management on March 22, 2024.
IGC Pharma enters ATM sales agreement for up to $60M in common stock
Agreement with A.G.P./Alliance Global Partners allows at-the-market sales of up to $60 million in common stock.
IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline
Terry Lierman appointed as independent Class B director, effective March 12, 2024.
On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.
Max materiality 0.85 · Median 0.55 · Most common event other_material